Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Obesity

Free Subscription Articles published in Lancet Retrieve available abstracts of 68 articles: HTML format

Single Articles

April 2024
1. THE LANCET EDITORS
   Retraction and republication-Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
   Lancet. 2024;403:1321.
   PubMed    
   
   
   
2. SHI Q, Wang Y, Hao Q, Vandvik PO, et al
   Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
   Lancet. 2024;403:e21-e31.
   PubMed     Abstract available
   
   
   
3. BUTLER J, Shah SJ, Petrie MC, Borlaug BA, et al
   Semaglutide versus placebo in people with obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF DM randomised trials.
   Lancet. 2024 Apr 4:S0140-6736(24)00469-0. doi: 10.1016/S0140-6736(24)00469.
   PubMed     Abstract available
   
   
   
4. DONAL E, L'Official G, Istratoaie S
   Semaglutide-a new treatment for obesity-related heart failure with preserved ejection fraction?
   Lancet. 2024 Apr 4:S0140-6736(24)00653-6. doi: 10.1016/S0140-6736(24)00653.
   PubMed    
   
   
   March 2024
5. JOHANSSON K, Bodnar LM, Stephansson O, Abrams B, et al
   Safety of low weight gain or weight loss in pregnancies with class 1, 2, and 3 obesity: a population-based cohort study.
   Lancet. 2024 Mar 28:S0140-6736(24)00255-1. doi: 10.1016/S0140-6736(24)00255.
   PubMed     Abstract available
   
   
   
6. GAILLARD R
   Optimising gestational weight gain among pregnant women with obesity.
   Lancet. 2024 Mar 28:S0140-6736(24)00470-7. doi: 10.1016/S0140-6736(24)00470.
   PubMed    
   
   
   February 2024
7. TUMAS N, Lopez SR
   Double burden of underweight and obesity: insights from new global evidence.
   Lancet. 2024 Feb 29:S0140-6736(24)00051-5. doi: 10.1016/S0140-6736(24)00051.
   PubMed    
   
   
   
8. 
   Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults.
   Lancet. 2024 Feb 29:S0140-6736(23)02750-2. doi: 10.1016/S0140-6736(23)02750.
   PubMed     Abstract available
   
   
   
9. CAMPBELL P, Rutten FH, Lee MM, Hawkins NM, et al
   Heart failure with preserved ejection fraction: everything the clinician needs to know.
   Lancet. 2024 Feb 14:S0140-6736(23)02756-3. doi: 10.1016/S0140-6736(23)02756.
   PubMed     Abstract available
   
   
   January 2024
10. THE LANCET
    Treating obesity and diabetes: drugs alone are not enough.
    Lancet. 2024;403:1.
    PubMed    
    
    
    December 2023
11. DANIELS JP
    Colombia introduces junk food tax.
    Lancet. 2023;402:2062.
    PubMed    
    
    
    November 2023
12. ZOU M, Northstone K, Leary S
    Causal effects of later-eating rhythm on adiposity in children through the comparison of two cohorts in the UK and China: a cross-cohort study.
    Lancet. 2023;402 Suppl 1:S99.
    PubMed     Abstract available
    
    
    
13. ALRUBAIAN F, Mulla Z
    Governments policy measures to address obesity among adults: a scoping review of the global evidence.
    Lancet. 2023;402 Suppl 1:S20.
    PubMed     Abstract available
    
    
    
14. CISNEROS AB, Headings R, Wells R, Reynolds C, et al
    Understanding the use of media analysis in public health research through food tax debates (HEALTHEI Project): a scoping review.
    Lancet. 2023;402 Suppl 1:S9.
    PubMed     Abstract available
    
    
    
15. SPAVIN A, Moore A, Lunn J, Tucker F, et al
    Reflecting on parental insights into healthy lifestyles: a qualitative study.
    Lancet. 2023;402 Suppl 1:S85.
    PubMed     Abstract available
    
    
    
16. CHEN S, Kuper H
    Tracing the temporal trends of modifiable risk factors in dementia: insights from the English Longitudinal Study of Ageing (2004-2019).
    Lancet. 2023;402 Suppl 1:S34.
    PubMed     Abstract available
    
    
    
17. WALSH S, Wallace L, Kuhn I, Mytton O, et al
    Population-level interventions for the primary prevention of dementia: a complex evidence review.
    Lancet. 2023;402 Suppl 1:S13.
    PubMed     Abstract available
    
    
    October 2023
18. KOTANI T, Tano S
    Long-term effects of gestational weight gain on mortality.
    Lancet. 2023 Oct 19:S0140-6736(23)01837-8. doi: 10.1016/S0140-6736(23)01837.
    PubMed    
    
    
    
19. HINKLE SN, Mumford SL, Grantz KL, Mendola P, et al
    Gestational weight change in a diverse pregnancy cohort and mortality over 50 years: a prospective observational cohort study.
    Lancet. 2023 Oct 19:S0140-6736(23)01517-9. doi: 10.1016/S0140-6736(23)01517.
    PubMed     Abstract available
    
    
    September 2023
20. SUMITHRAN P, Finucane FM, Cohen RV
    Obesity drug shortages are symptomatic of wider malaise.
    Lancet. 2023 Sep 29:S0140-6736(23)01963-3. doi: 10.1016/S0140-6736(23)01963.
    PubMed    
    
    
    June 2023
21. GARVEY WT, Frias JP, Jastreboff AM, le Roux CW, et al
    Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
    Lancet. 2023 Jun 26:S0140-6736(23)01200-X. doi: 10.1016/S0140-6736(23)01200.
    PubMed     Abstract available
    
    
    
22. APOVIAN CM, McDonnell ME
    CagriSema and the link between obesity and type 2 diabetes.
    Lancet. 2023 Jun 23:S0140-6736(23)01291-6. doi: 10.1016/S0140-6736(23)01291.
    PubMed    
    
    
    
23. KNOP FK, Aroda VR, do Vale RD, Holst-Hansen T, et al
    Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Lancet. 2023 Jun 23:S0140-6736(23)01185-6. doi: 10.1016/S0140-6736(23)01185.
    PubMed     Abstract available
    
    
    
24. FALLOWS E, Ells L, Anand V
    Semaglutide and the future of obesity care in the UK.
    Lancet. 2023 Jun 5:S0140-6736(23)01083-8. doi: 10.1016/S0140-6736(23)01083.
    PubMed    
    
    
    May 2023
25. SKYLE D
    Fatima Cody Stanford: changing the narrative on obesity.
    Lancet. 2023;401:1644.
    PubMed    
    
    
    April 2023
26. MAHGOUB S, Newsome PN
    Bariatric-metabolic surgery versus lifestyle intervention in non-alcoholic steatohepatitis.
    Lancet. 2023 Apr 20:S0140-6736(23)00773-0. doi: 10.1016/S0140-6736(23)00773.
    PubMed    
    
    
    
27. VERRASTRO O, Panunzi S, Castagneto-Gissey L, De Gaetano A, et al
    Bariatric-metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trial.
    Lancet. 2023 Apr 20:S0140-6736(23)00634-7. doi: 10.1016/S0140-6736(23)00634.
    PubMed     Abstract available
    
    
    February 2023
28. PERDOMO CM, Cohen RV, Sumithran P, Clement K, et al
    Contemporary medical, device, and surgical therapies for obesity in adults.
    Lancet. 2023 Feb 9:S0140-6736(22)02403-5. doi: 10.1016/S0140-6736(22)02403.
    PubMed     Abstract available
    
    
    December 2022
29. KRAMER CK, Leitao CB, Viana LV
    The impact of urbanisation on the cardiometabolic health of Indigenous Brazilian peoples: a systematic review and meta-analysis, and data from the Brazilian Health registry.
    Lancet. 2022;400:2074-2083.
    PubMed     Abstract available
    
    
    November 2022
30. KRENZ K, McEachan R, Subiza-Perez M, Watmuff A, et al
    Exploring relationships between exposure to fast food outlets and childhood obesity at differing spatial resolutions: results from the Born in Bradford cohort study.
    Lancet. 2022;400 Suppl 1:S55.
    PubMed     Abstract available
    
    
    
31. HESLEHURST N, Evans EH, Rodriguez ACI, Nagpal TS, et al
    Newspaper media framing of maternal obesity in the UK: a review and framework synthesis.
    Lancet. 2022;400 Suppl 1:S48.
    PubMed     Abstract available
    
    
    
32. BIJLANI C, Vrinten C, Chang K, Hrobonova E, et al
    Changes in diet and physical activity after a pilot intervention to tackle childhood obesity in a deprived inner-London community: an observational cohort study.
    Lancet. 2022;400 Suppl 1:S22.
    PubMed     Abstract available
    
    
    
33. BEYNON C
    Exploring the association between obesity and problems with peer relationships in children: a nationally representative cross-sectional study.
    Lancet. 2022;400 Suppl 1:S21.
    PubMed     Abstract available
    
    
    October 2022
34. URVA S, Coskun T, Loh MT, Du Y, et al
    LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.
    Lancet. 2022 Oct 27. pii: S0140-6736(22)02033.
    PubMed     Abstract available
    
    
    July 2022
35. ABU DAYYEH BK, Bazerbachi F, Vargas EJ, Sharaiha RZ, et al
    Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial.
    Lancet. 2022 Jul 28. pii: S0140-6736(22)01280.
    PubMed     Abstract available
    
    
    June 2022
36. GOLUBIC R, Barber TM, Caleyachetty R
    Obesity definition for personalised treatment of type 2 diabetes.
    Lancet. 2022;399:2189.
    PubMed    
    
    
    
37. LINGVAY I, Sumithran P, Cohen RV, Roux CWL, et al
    Obesity definition for personalised treatment of type 2 diabetes Authors' reply.
    Lancet. 2022;399:2189-2190.
    PubMed    
    
    
    
38. SHI Q, Wang Y, Li S
    Pharmacotherapy for adults with overweight and obesity - Authors' reply.
    Lancet. 2022;399:2101.
    PubMed    
    
    
    
39. DAYYEH BKA
    Adjustable intragastric balloon for obesity - Author's reply.
    Lancet. 2022;399:2100.
    PubMed    
    
    
    
40. STURGISS E, Ball L, Blane D, Hennessy M, et al
    Pharmacotherapy for adults with overweight and obesity.
    Lancet. 2022;399:2100-2101.
    PubMed    
    
    
    
41. CHARALAMPAKIS V, Rajeev Y, Singhal R
    Adjustable intragastric balloon for obesity.
    Lancet. 2022;399:2099.
    PubMed    
    
    
    
42. BRUNALDI VO, Neto MG
    Adjustable intragastric balloon for obesity.
    Lancet. 2022;399:2099.
    PubMed    
    
    
    April 2022
43. CROSBIE EJ, Kitson SJ, McAlpine JN, Mukhopadhyay A, et al
    Endometrial cancer.
    Lancet. 2022;399:1412-1428.
    PubMed     Abstract available
    
    
    February 2022
44. TATUM M
    China's population peak.
    Lancet. 2022;399:509.
    PubMed    
    
    
    December 2021
45. SHI Q, Wang Y, Hao Q, Vandvik PO, et al
    Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.
    Lancet. 2021 Dec 8. pii: S0140-6736(21)01640.
    PubMed     Abstract available
    
    
    November 2021
46. LAU DCW, Erichsen L, Francisco AM, Satylganova A, et al
    Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
    Lancet. 2021 Nov 16. pii: S0140-6736(21)01751.
    PubMed     Abstract available
    
    
    
47. ABU DAYYEH BK, Maselli DB, Rapaka B, Lavin T, et al
    Adjustable intragastric balloon for treatment of obesity: a multicentre, open-label, randomised clinical trial.
    Lancet. 2021 Nov 15. pii: S0140-6736(21)02394.
    PubMed     Abstract available
    
    
    
48. SUDLOW A, le Roux CW
    Improving gastric balloons to treat obesity.
    Lancet. 2021 Nov 15. pii: S0140-6736(21)02505.
    PubMed    
    
    
    September 2021
49. LINGVAY I, Sumithran P, Cohen RV, le Roux CW, et al
    Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation.
    Lancet. 2021 Sep 30. pii: S0140-6736(21)01919.
    PubMed     Abstract available
    
    
    August 2021
50. MEGHJI J, Mortimer K, Jayasooriya S, Marks GB, et al
    Lung health in LMICs: tackling challenges ahead - Authors' reply.
    Lancet. 2021;398:490.
    PubMed    
    
    
    
51. NEMERY B, Katoto PDMC, Develtere P
    Lung health in LMICs: tackling challenges ahead.
    Lancet. 2021;398:489-490.
    PubMed    
    
    
    
52. KHOO EM, Li D, Ungan M, Jordan R, et al
    Lung health in LMICs: tackling challenges ahead.
    Lancet. 2021;398:488-489.
    PubMed    
    
    
    July 2021
53. TEUFEL F, Seiglie JA, Geldsetzer P, Theilmann M, et al
    Body-mass index and diabetes risk in 57 low-income and middle-income countries: a cross-sectional study of nationally representative, individual-level data in 685 616 adults.
    Lancet. 2021;398:238-248.
    PubMed     Abstract available
    
    
    
54. WANG L, Zhou B, Zhao Z, Yang L, et al
    Body-mass index and obesity in urban and rural China: findings from consecutive nationally representative surveys during 2004-18.
    Lancet. 2021;398:53-63.
    PubMed     Abstract available
    
    
    
55. FLEGAL KM
    BMI and obesity trends in Chinese national survey data.
    Lancet. 2021;398:5-7.
    PubMed    
    
    
    
56. SALAH RO, Ghandour R, Husseini A
    Prevalence of overweight, obesity, and associated factors among adolescents in the occupied Palestinian territory: a cross-sectional study.
    Lancet. 2021;398 Suppl 1:S46.
    PubMed     Abstract available
    
    
    June 2021
57. TREASURE J, Ambwani S
    Addressing weight stigma and anti-obesity rhetoric in policy changes to prevent eating disorders.
    Lancet. 2021 Jun 3. pii: S0140-6736(21)01109.
    PubMed    
    
    
    May 2021
58. MINGRONE G, Bornstein SR
    Gain in survival after metabolic-bariatric surgery.
    Lancet. 2021;397:1785-1787.
    PubMed    
    
    
    
59. ENEBO LB, Berthelsen KK, Kankam M, Lund MT, et al
    Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2.4 mg for weight management: a randomised, controlled, phase 1b trial.
    Lancet. 2021;397:1736-1748.
    PubMed     Abstract available
    
    
    
60. SYN NL, Cummings DE, Wang LZ, Lin DJ, et al
    Association of metabolic-bariatric surgery with long-term survival in adults with and without diabetes: a one-stage meta-analysis of matched cohort and prospective controlled studies with 174 772 participants.
    Lancet. 2021 May 6. pii: S0140-6736(21)00591.
    PubMed     Abstract available
    
    
    April 2021
61. BECERRIL S, Fruhbeck G
    Cagrilintide plus semaglutide for obesity management.
    Lancet. 2021 Apr 22. pii: S0140-6736(21)00944.
    PubMed    
    
    
    March 2021
62. LATINI R, Staszewsky L
    Semaglutide and effective weight control.
    Lancet. 2021;397:942-943.
    PubMed    
    
    
    
63. DAVIES M, Faerch L, Jeppesen OK, Pakseresht A, et al
    Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial.
    Lancet. 2021 Mar 2. pii: S0140-6736(21)00213.
    PubMed     Abstract available
    
    
    November 2020
64. CHAN JCN, Lim LL, Wareham NJ, Shaw JE, et al
    The Lancet Commission on diabetes: using data to transform diabetes care and patient lives.
    Lancet. 2020 Nov 12. pii: S0140-6736(20)32374.
    PubMed    
    
    
    September 2020
65. HAWKES C, Ruel M, Wells JC, Popkin BM, et al
    The double burden of malnutrition-further perspective - Authors' reply.
    Lancet. 2020;396:815-816.
    PubMed    
    
    
    
66. STEWART CP, de Pee S, Maleta K, Michaelsen KF, et al
    The double burden of malnutrition-further perspective.
    Lancet. 2020;396:814-815.
    PubMed    
    
    
    
67. OSENDARP SJM, Brown KH, Neufeld LM, Udomkesmalee E, et al
    The double burden of malnutrition-further perspective.
    Lancet. 2020;396:813.
    PubMed    
    
    
    
68. HOSSAIN MS, Ferdous S, Raheem E, Siddiqee MH, et al
    The double burden of malnutrition-further perspective.
    Lancet. 2020;396:813-814.
    PubMed    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Obesity is free of charge.